In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HTG Molecular Diagnostics Inc.

www.htgmolecular.com

Latest From HTG Molecular Diagnostics Inc.

Immuno-Oncology Is Making Pharma Step Up Its Diagnostics Game

Immuno-oncology has significant diagnostic needs including identifying patients most likely to respond to therapies. Current diagnostic approaches often fall short, due in large part to the complexity of the biology driving therapy responsiveness. As such, the biopharma industry is exploring many emerging approaches covering tumor, immune and even microbiome-related pathways and biomarkers.

ImmunoOncology Diagnostics

Deals Shaping The Medical Industry, February 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.

Deals Medical Device

Execs On The Move, April 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Device/Diagnostics Quarterly Deal Statistics, Q2 2016

Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.

Deals Market Intelligence
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • High Throughput Genomics Inc.
  • HTG Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • HTG Molecular Diagnostics Inc.
  • Senior Management
  • Timothy B Johnson, CEO
    Shaun McMeans, VP, Fin., Admin. & CFO
    John Lubniewski, Pres. & COO
    Patrick Roche, PhD, SVP, R&D
  • Contact Info
  • HTG Molecular Diagnostics Inc.
    Phone: (877) 289-2615
    3430 E. Global Loop
    Tucson, AZ 85706
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register